Exhibiting at booth 5

MedCity is the life sciences organisation for London and the greater south east of England, incorporating the Golden Triangle of Cambridge – London – Oxford.  The region is home to world-class academic institutions including King’s College London, Imperial College London, Queen Mary University of London, UCL, The Francis Crick Institute, The Institute of Cancer Research and the Universities of Oxford and Cambridge.

MedCity provides a front door into the life sciences ecosystem for companies, investors and the life sciences real estate sector.  MedCity can help to connect you to find the expertise, resources, infrastructure, places and people needed to grow your company and we support companies to understand the route to market and regulatory frameworks.
MedCity works across all human health focused life sciences modalities – advanced therapies, biopharmaceuticals, medical technologies, diagnostics, digital health, data and AI applied to healthcare.

MedCity connects excellence across academic centres, the health service (NHS) and industry.

Ilias Zapantis
Programme Manager 
Phil Jackson
Project Director 


Medherant is developing a pipeline of products for pain and neurology indications, based on our next-generation TEPI-Patch® transdermal drug technology. Our first product – Ibuprofen TEPI Patch – entered the clinic in 2018.

Key advantages of the TEPI Patch® technology over current technologies are the high payload and very efficient release of drug.  This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch whilst also minimising the residual drug after use.  

The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove. No organic solvents are involved in this drug-in-adhesive system.

As well as developing our own products, Medherant offers pharma companies rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of their drugs of interest.

Nigel Davis


The Life Science Network for Wales

Founded in 1992, MediWales is the life science network and representative body for Wales. MediWales provides advice, support and business opportunities for our members, whilst promoting collaboration within the life science and health technology community in Wales.

With 180 members, our network is largely made up of life science organisations, pharmaceutical services and medical technology companies. We actively encourage engagement with the clinical research community and our membership includes NHS health boards and universities. We are an independent, not-for-profit limited company.

Our mission is ‘The advancement of human life science in Wales.’ 

Our focus is creating opportunities for our members.

Organisation type
Debbie Laubach
Operations Manager 

Mereo BioPharma Group plc


Our mission is to provide new therapies to patients with chronically debilitating and life limiting rare diseases that have few, if any, other treatment options.

Our goal is to build an international biopharmaceutical company developing and commercializing new therapies for rare disease patients, focusing on bone/musculoskeletal, respiratory and endocrine indications.


Our clinical-stage, rare disease assets originated in pharmaceutical or biotechnology companies where for strategic reasons they were not being progressed. With the streamlined efficiency of a small company and with our internal expertise and external resources we are able to rapidly progress the products into late stage development and the planned subsequent commercialization. 

Donald Coppen
Director of Corporate Development 
Pascal Venn
Manager, Corporate Development 


We aim to improve the health and quality of life of patients by creating high value therapeutics addressing global unmet medical needs.

Mironid® is a vibrant, growing, customer-centric company with an outstanding team motivated to deliver innovative new medicines.Our mission is to become a world leader in cell signalling directed therapeutic development.Mironid® is currently building and progressing a pipeline of early stage drug discovery programmes that are initially targeted at cAMP degrading phosphodiesterase enzymes. These will generate novel and differentiated therapies for a range of therapeutic indications.

Neil Wilkie